CASE STUDY

Reference Drug Aliquots: The right control for Assays

“Evidentic’s Drug aliquots helped us to ascertain the efficacy of our novel molecule [in comparison to commercial therapeutic antibody] which supported our fundraising efforts.”
Pavel Khrimian
Co-founder & CBO at Deka Biosciences Inc
Dr John Mumm and Pavel Khrimian co-founded Deka in Jan 2019. They have developed candidate molecules for the treatment of life-threatening diseases using targeted cytokine delivery platform Diakine™ coupled with a precision medicine strategy. Their current focus is on oncology and inflammatory diseases such as Crohn’s, sepsis, and psoriasis. This narrative is the result of the June 10th, 2020 interview with Pavel Khrimian. The content has been edited for clarity.

Why was it important to evaluate the current commercial drugs during Diakine® development?

The commercial drugs provide a very good reference point for novel molecule development. They are often used as comparators in drug development.

What were your challenges before finding Evidentic?

The use of biosimilars was just not good enough for our target audience, who wanted to see in-vivo data of our novel Diakine™ compared to a commercial therapeutic drug. We are very fortunate that we found Evidentic, as there were no other sources of therapeutic drugs that were readily available.

How did Evidentic help you?

We were able to effectively eliminate the questions by using the drug aliquots of therapeutic drugs from Evidentic to show the superiority of our Diakine™ in a mouse model. Evidentic provides quality products with exceptional customer service, which enables an early-stage startup such as Deka Biosciences to succeed.

more case studies

NIBRT

National Institute for Bioprocessing Research and Training (NIBRT)

Quality and Service: Fast and easy ordering processes meet the needs in highly work-intense phase

“We are thankful and more than happy to work with the Evidentic. Not only are the drug aliquots in the best quality and satisfy our requests to the full extent, but also can we absolutely rely on the whole Evidentic team."
Sara Carillo | NBRIT
Sara Carillo
Bioanalytical Research Lead, National Institute for Bioprocessing Research and Training (NIBRT)/Ireland

ICNAS

Academia: Optimize and validate research protocols with mAb drug aliquots

“Evidentic was the only source that offered small aliquots of original therapeutic mAbs at an affordable price range. The aliquots came in an easy-to-use-and-store format that was apt for my research purpose.”
IvannaH-e1616487869155
Ivanna Hrynchak
PhD Student, ICNAS, Universidade d Coimbra, Portugal

ExcellGene

Biosimilars: Reference Drug Aliquots for Faster Selection and Development of CHO-based Production Processes

“Evidentic drug aliquots have helped us speed up our antibody characterization assays and selection of clonal cell lines. An easy and reliable source!”
staff-florian
Prof. (emeritus) Dr. Florian Wurm
Chief Scientific Officer and Founder, ExcellGene SA

UGA Biopharma GmbH

Aliquots: A New Solution to the Batch Variability Problem

“Evidentic drug aliquots have significantly reduced our development cycle time and strengthened our ability to do detailed [protein] characterization.”
Dr-Stephan-Schultz
Dr Stephan Schultz
Team Leader of Analytics/DSP at UGA Biopharma GmbH

Deka BioSciences

Reference Drug Aliquots: The right control for Assays

“Evidentic’s Drug aliquots helped us to ascertain the efficacy of our novel molecule [in comparison to commercial therapeutic antibody] which supported our fundraising efforts.”
pavel_-234x234
Pavel Khrimian
Co-founder & CBO at Deka Biosciences Inc

Evidentic GmbH
Am Mühlenberg 10

14476 Potsdam | Germany

+49 (0) 30 959 99 8831
info@evidentic.com

Cookie Preferences

Linkedin Youtube Facebook Twitter Instagram